Xeris Biopharma opened higher at $16.69, compared with its previous close of $16.52. In the last trading session, the stock traded between $16.35 and $16.88. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Xeris Biopharma is now worth
$ 800.58
Giving a profit of
$ 700.58 (700.58%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
+$0.13 (+0.80%)
Day High
$16.88
Day Low
$16.35
Day Open
$16.69
Prev Close
$16.52
Volume
17,18,518
1W Return
59.03%
1M Return
59.11%
3M Return
98.64%
6M Return
171.21%
1Y Return
123.82%
Fundamentals
Market Cap ($ Mn)
3,042
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
10.28%
EPS (TTM)
$0.06
Investment Returns
1 Week
59.03%
1 Month
59.11%
3 Months
98.64%
6 Months
171.21%
9 Months
140.98%
Financials
Quarterly
All values in $ Mn
60.1
Mar 25
71.5
Jun 25
74.4
Sep 25
85.8
Dec 25
92.1
Jun 26
107.2
Sep 26
Updates
11Nov
Barclays raises Xeris Biopharma price target to $18, keeps Overweight
Barclays raises Xeris Biopharma price target from $14 to $18. Analyst Glen Santangelo maintains Overweight rating on the stock. New target aligns with previous $18 benchmark set by HC Wainwright. Oppenheimer recently increased its target to $21, citing strong outlook.
Yesterday
14Oct
Xeris Biopharma files patent infringement suits against Torrent and Rising
Filed patent infringement suits in New Jersey District Court on October 13, 2026. Defendants include Torrent Pharma group and Rising Pharma entities. Allegations center on violation of U.S. Patent No. 12,758,502 for Keyevis. Seeking injunctive relief, monetary damages, and attorneys' fees.
29 days ago
3Oct
Xeris Biopharma grants equity awards to 60 new employees
Granted equity awards for 352,170 shares to 60 new employees. Non-qualified stock options priced at $9.25 per share. Awards vest over three years in equal annual installments.
1mo ago
29Sep
Lundbeck reportedly expresses interest in buying Xeris Biopharma
Lundbeck has expressed interest in buying Xeris Biopharma. Report sourced from Bloomberg. Deal details and valuation remain undisclosed.
Xeris plans to initiate Phase 3 Cornerstone study by year-end for XP-8121. Topline results expected in late 2028 with FDA approval targeted for 2030. Company projects peak net revenue potential of $1 billion to $3 billion. Study enrolls 500 patients across 50+ sites to test therapeutic equivalence.
2mo ago
26Aug
Xeris schedules webinar to detail XP-8121 Phase 3 program
Xeris will host a webinar on September 9, 2026, at 10 a.m. ET to discuss XP-8121. The session will cover trial design, endpoints, and regulatory timelines for Phase 3. XP-8121 is a once-weekly subcutaneous injection for hypothyroidism. CEO John Shannon highlighted GI absorption issues with current oral therapies.
